Company Description
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 1987 |
| IPO Date | Dec 5, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,543 |
| CEO | John Jacobs |
Contact Details
Address: 700 Quince Orchard Road Gaithersburg, Maryland 20878 United States | |
| Phone | 240 268 2000 |
| Website | novavax.com |
Stock Details
| Ticker Symbol | NVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000694 |
| CUSIP Number | 670002401 |
| ISIN Number | US6700024010 |
| Employer ID | 22-2816046 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Jacobs | Chief Executive Officer |
| James Kelly | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 2, 2025 | 144/A | Filing |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 26, 2024 | 144 | Filing |
| Dec 18, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 144 | Filing |
| Dec 4, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |